Literature DB >> 9566468

Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis.

A A Stinnett1, J Mullahy.   

Abstract

In recent years, considerable attention has been devoted to the development of statistical methods for the analysis of uncertainty in cost-effectiveness (CE) analysis, with a focus on situations in which the analyst has patient-level data on the costs and health effects of alternative interventions. To date, discussions have focused almost exclusively on addressing the practical challenges involved in estimating confidence intervals for CE ratios. However, the general approach of using confidence intervals to convey information about uncertainty around CE ratio estimates suffers from theoretical limitations that render it inappropriate in many situations. The authors present an alternative framework for analyzing uncertainty in the economic evaluation of health interventions (the "net health benefits" approach) that is more broadly applicable and that avoids some problems of prior methods. This approach offers several practical and theoretical advantages over the analysis of CE ratios, is straightforward to apply, and highlights some important principles in the theoretical underpinnings of CE analysis.

Entities:  

Mesh:

Year:  1998        PMID: 9566468     DOI: 10.1177/0272989X98018002S09

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  297 in total

Review 1.  Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio.

Authors:  A O'Hagan; J W Stevens; J Montmartin
Journal:  Pharmacoeconomics       Date:  2000-04       Impact factor: 4.981

Review 2.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 3.  Willingness to pay as a measure of health benefits.

Authors:  M V Bala; J A Mauskopf; L L Wood
Journal:  Pharmacoeconomics       Date:  1999-01       Impact factor: 4.981

4.  The cost effectiveness of two new antiepileptic therapies in the absence of direct comparative data: a first approximation.

Authors:  Ben A van Hout; Dennis D Gagnon; Pauline McNulty; Anthony O'Hagan
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

5.  Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.

Authors:  Martin E Backhouse
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Authors:  Niklas Zethraeus; Magnus Johannesson; Bengt Jönsson; Mickael Löthgren; Magnus Tambour
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

7.  Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting.

Authors:  Marcus A Neubauer; J Russell Hoverman; Michael Kolodziej; Lonny Reisman; Stephen K Gruschkus; Susan Hoang; Albert A Alva; Marilyn McArthur; Michael Forsyth; Todd Rothermel; Roy A Beveridge
Journal:  J Oncol Pract       Date:  2009-12-30       Impact factor: 3.840

8.  Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.

Authors:  Helen Dakin; Morris Sherman; Scott Fung; Carrie Fidler; Anthony Bentley
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

9.  Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

Authors:  Annemieke De Ridder; Diana De Graeve
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Calculating the Expected Value of Sample Information in Practice: Considerations from 3 Case Studies.

Authors:  Anna Heath; Natalia Kunst; Christopher Jackson; Mark Strong; Fernando Alarid-Escudero; Jeremy D Goldhaber-Fiebert; Gianluca Baio; Nicolas A Menzies; Hawre Jalal
Journal:  Med Decis Making       Date:  2020-04-16       Impact factor: 2.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.